OasisLMS

In the first session of the ACCC Knowledge Series, Optimizing Patient Outcomes with ADCs in Gynecologic Malignancies, Marilyn Huang, MD, MS, and Premal H. Thaker, MD, review the application of antibody-drug conjugates in gynecologic cancers, their adverse events, and mitigation strategies. 

In the second session of the 2-part ACCC Knowledge Series, Optimizing Patient Outcomes with ADCs in Gynecologic Malignancies, Cynthia Ryan, PharmD, BCPS, reviews best practices for monitoring and managing adverse events with antibody-drug conjugates for gynecologic malignancies. 

Learning objectives: 

• Understand current indications for ADCs in gynecologic malignancies and future ADCs in development 
• Use clinical data on ADCs to inform treatment decisions across gynecologic cancer types 
• Identify and manage common adverse events associated with ADCs.